SBIO Rallies on M&A Announcements
The ALPS Medical Breakthroughs ETF (SBIO) rallied 14.53% last week, propelled by positive earnings and two significant M&A announcements in the portfolio.
Stay updated with breaking news from Compass Pathways. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The ALPS Medical Breakthroughs ETF (SBIO) rallied 14.53% last week, propelled by positive earnings and two significant M&A announcements in the portfolio.
Investegate announcements from COMPASS Pathways, COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Highlights: Kabir Nath appointed as Chief Executive Officer Phase III program submitted to FDA...
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which...
Investegate announcements from COMPASS Pathways, COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa